393 related articles for article (PubMed ID: 26288093)
1. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.
Gu L; Han Y; Li Y; Zhu T; Song X; Huang Y; Yang F; Guan S; Xie J; Gohda J; Hosoya N; Kawana-Tachikawa A; Liu W; Gao GF; Iwamoto A; Li T; Ishida T
PLoS One; 2015; 10(8):e0134539. PubMed ID: 26288093
[TBL] [Abstract][Full Text] [Related]
2. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
[TBL] [Abstract][Full Text] [Related]
3. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
Pal A; Sarkar N; Saha D; Guha SK; Saha B; Chakrabarti S; Chakravarty R
Antivir Ther; 2015; 20(5):545-54. PubMed ID: 25654813
[TBL] [Abstract][Full Text] [Related]
4. High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
Jia HH; Li KW; Chen QY; Wang XY; Harrison TJ; Liang SJ; Yang QL; Wang C; Hu LP; Ren CC; Fang ZL
Intervirology; 2018; 61(3):123-132. PubMed ID: 30368502
[TBL] [Abstract][Full Text] [Related]
5. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC
PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
Li Y; Xie J; Han Y; Wang H; Zhu T; Wang N; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Thio CL; Li T
J Acquir Immune Defic Syndr; 2016 May; 72(1):39-45. PubMed ID: 26745828
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Alvarez-Uria G; Ratcliffe L; Vilar J
HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
[TBL] [Abstract][Full Text] [Related]
8. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
Kouanfack C; Aghokeng AF; Mondain AM; Bourgeois A; Kenfack A; Mpoudi-Ngolé E; Ducos J; Delaporte E; Laurent C
Antivir Ther; 2012; 17(2):321-6. PubMed ID: 22290198
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
11. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
[TBL] [Abstract][Full Text] [Related]
12. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
13. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
[TBL] [Abstract][Full Text] [Related]
14. HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
Archampong TN; Boyce CL; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Blackard JT; Kwara A
Antivir Ther; 2017; 22(1):13-20. PubMed ID: 27167598
[TBL] [Abstract][Full Text] [Related]
15. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China.
Wu YS; Zhang WW; Ling XM; Yang L; Huang SB; Wang XC; Wu H; Cai WP; Wang M; Wang H; Liu YF; He HL; Wei FL; Wu ZY; Zhang FJ
Chin Med J (Engl); 2016 Feb; 129(3):304-8. PubMed ID: 26831232
[TBL] [Abstract][Full Text] [Related]
17. Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents.
Aurpibul L; Lumbiganon P; Hansudewechakul R; Kanjanavanit S; Bunupuradah T; Kosalaraksa P; Taeprasert P; Puthanakit T
Pediatr Infect Dis J; 2017 Apr; 36(4):401-404. PubMed ID: 28005687
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B Virus (HBV) Load Response to 2 Antiviral Regimens, Tenofovir/Lamivudine and Lamivudine, in HIV/ HBV-Coinfected Pregnant Women in Guangxi, China: The Tenofovir in Pregnancy (TiP) Study.
Wang L; Wiener J; Bulterys M; Wei X; Chen L; Liu W; Liang S; Shepard C; Wang L; Wang A; Zhang F; Kourtis AP
J Infect Dis; 2016 Dec; 214(11):1695-1699. PubMed ID: 27658693
[TBL] [Abstract][Full Text] [Related]
19. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.
Lukhwareni A; Gededzha MP; Amponsah-Dacosta E; Blackard JT; Burnett RJ; Selabe SG; Kyaw T; Mphahlele MJ
Viruses; 2020 Jun; 12(6):. PubMed ID: 32545313
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]